Pharmacokinetics of [14C]ciclesonide after oral and intravenous administration to healthy subjects

Clinical Pharmacokinetics

Volumn 43, Issue 7, 2004, Pages 479-486

  Nave, Ruediger ^a   Bethke, Thomas D ^a   Van Marle, Sjoerd P ^b   Zech, Karl ^a  

^a ALTANA PHARMA AG   (Germany)

^b PRA International USA   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; CICLESONIDE; PREGNANE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG TOLERABILITY; DRUG URINE LEVEL; ERYTHROCYTE; FECES ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TANDEM MASS SPECTROMETRY; BIOAVAILABILITY; BLOOD; HALF LIFE TIME; INTESTINE ABSORPTION; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; INTESTINAL ABSORPTION; MALE; PREGNENEDIONES;

EID: 2642522877     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200443070-00004     Document Type: Article

References (22)

1. Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med 1995; 332: 868-75
2. Beasley R, Crane J, Lai CK, et al. Prevalence and etiology of asthma. J Allergy Clin Immunol 2000; 105: S466-72
3. Yang KD. Childhood asthma: aspects of global environment, genetics and management. Changgeng Yi Xue Za Zhi 2000; 23: 641-61
4. Woolcock AJ, Bastiampillai SA, Marks GB, et al. The burden of asthma in Australia. Med J Aust 2001; 175: 141-5
5. Blake KV. Drug treatment of airway inflammation in asthma. Pharmacotherapy 2001; 21: 3S-20S
6. Busse WW, Lemanske RFJ. Asthma. N Engl J Med 2001; 344: 350-62
7. Stirling RG, Chung KF. Future treatments of allergic diseases and asthma. Br Med Bull 2000; 56: 1037-53
8. Kumana CR, Kou M, Lauder IJ, et al. Increasing use of inhaled steroids associated with declining asthma mortality. J Asthma 2001; 38: 161-7
9. Barnes PJ, Pedersen S. Efficacy and safety of inhaled corticosteroids in asthma. Report of a workshop held in Eze, France, October 1992. Am Rev Respir Dis 1993; 148: S1-26
10. van Staa TP, Leufkens HG, Cooper C. Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res 2001; 16: 581-8
11. Leech JA, Hodder RV, Ooi DS, et al. Effects of short-term inhaled budesonide and beclomethasone dipropionate on serum osteocalcin in premenopausal women. Am Rev Respir Dis 1993; 148: 113-5
12. Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 1997; 337: 8-14
13. Taylor DA, Jensen MW, Kanabar V, et al. A dose-dependent effect of the novel inhaled corticosteroid ciclesonide on airway responsiveness to adenosine-5′-monophosphate in asthmatic patients. Am J Respir Crit Care Med 1999; 160: 237-43
14. Schmidt BM, Timmer W, Georgens AC, et al. The new topical steroid ciclesonide is effective in the treatment of allergic rhinitis. J Clin Pharmacol 1999; 39: 1062-9
15. Kanniess F, Richter K, Bohme S, et al. Effect of inhaled ciclesonide on airway responsiveness to inhaled AMP, the composition of induced sputum and exhaled nitric oxide in patients with mild asthma. Pulm Pharmacol Ther 2001; 14: 141-7
16. Rohatagi S, Arya V, Zech K, et al. Population pharmacokinetics and pharmacodynamics of ciclesonide. J Clin Pharmacol 2003; 43: 365-78
17. Weinbrenner A, Hüneke D, Zschiesche M, et al. Circadian rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide. J Clin Endocrinol Metab 2002; 87: 2160-3
18. Hall M, Peet CF, Boddington TKS, et al. Enzymology of the human hepatic metabolism of ciclesonide (B9207-015). Xenobiotic Metab Dispos 2000; Suppl. 15: 12
19. Ryrfeldt A, Andersson P, Edsbacker S, et al. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis Suppl 1982; 122: 86-95
20. Falcoz C, Mackie A, McDowall J. Oral bioavailability of fluticasone propionate in healthy subjects. Br J Clin Pharmacol 1996; 41: 459P-60P
21. Minto C, Li B, Tattam B, et al. Pharmacokinetics of epimeric budesonide and fluticasone propionate after repeat dose inhalation -intersubject variability in systemic absorption from the lung. Br J Clin Pharmacol 2000; 50: 116-24
22. Rohatagi S, Appajosyula S, Derendorf H, et al. Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective. J Clin Pharmacol 2004; 44: 37-47